...
首页> 外文期刊>Journal of travel medicine. >Efficacy of rifaximin in prevention of travelers' diarrhea: A meta-analysis of randomized, double-blind, placebo-controlled trials
【24h】

Efficacy of rifaximin in prevention of travelers' diarrhea: A meta-analysis of randomized, double-blind, placebo-controlled trials

机译:利福昔明预防旅行者腹泻的功效:一项随机,双盲,安慰剂对照试验的荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background. Rifaximin has been used successfully for the prevention of travelers' diarrhea (TD), the most general cause of disability among international travelers to developing tropical and semitropical regions. Methods. We sought to better evaluate the efficacy of rifaximin in the prevention of TD. Randomized controlled trials (RCTs) of rifaximin for the prevention of TD published in Pubmed, the Cochrane Central Register of Controlled Trials, Embase, and the Science Citation Index were searched. [Correction added on 3 October 2012, after first online publication: the phrase "protection of TD" was replaced with "prevention of TD".] The primary efficacy outcome was occurrence of TD over a 2-week treatment period. Secondary outcomes were requirement for antibiotic treatment, occurrence of mild diarrhea (MD), occurrence of TD in the third week after drug withdrawal, incidence of TD associated with isolation of diarrheagenic Escherichia coli (ie, ETEC, EAEC), and adverse events. Results. Four RCTs with 502 participants were included in the systematic review. Rifaximin treatment showed a significant protection against TD (risk ratios, RR: 0.41, 95% CI: 0.30-0.56, p < 0.00001) and needed antibiotic-treated TD (relative risk [RR]: 0.30, 95% confidence interval [CI]: 0.18-0.49, p < 0.00001). There was no significant difference between rifaximin and placebo in the occurrence of MD (RR: 1.11, 95% CI: 0.78-1.59, p=0.55) and the occurrence of TD in the third week after drug withdrawal (RR: 0.73, 95% CI: 0.30-1.73, p=0.47). Enterotoxigenic E. coli was the major cause of TD, and all trials reported no differences in adverse events between rifaximin and placebo. Conclusions. Rifaximin can prevent TD caused by non-invasive enteric pathogens. Further research is needed for the treatment of invasive enteric pathogens. [Correction added on 3 October 2012, after first online publication: the phrase "Rifaximin can protect TD" was replaced with "Rifaximin can prevent TD".]
机译:背景。利福昔明已成功用于预防旅行者腹泻(TD),腹泻是发展中的热带和亚热带地区的国际旅行者中造成残疾的最普遍原因。方法。我们试图更好地评估利福昔明预防TD的疗效。搜索利福昔明预防TD的随机对照试验(RCT),该出版物发表于Pubmed,Cochrane对照试验中央登记册,Embase和《科学引文索引》。 [2012年10月3日,首次在线发布后修正:用“预防TD”代替“保护TD”。]主要疗效结果是在2周的治疗期内发生TD。次要结局是需要抗生素治疗,轻度腹泻(MD)发生,停药后第三周发生TD,与腹泻性大肠杆菌(即ETEC,EAEC)分离相关的TD发生率以及不良事件。结果。该系统评价包括四个有502名参与者的RCT。利福昔明治疗显示对TD具有显着保护作用(风险比,RR:0.41,95%CI:0.30-0.56,p <0.00001),需要抗生素治疗的TD(相对风险[RR]:0.30,95%置信区间[CI]) :0.18-0.49,p <0.00001)。利福昔明和安慰剂之间在停药后第三周的MD(RR:1.11,95%CI:0.78-1.59,p = 0.55)和TD的发生方面无显着差异(RR:0.73,95%) CI:0.30-1.73,p = 0.47)。产肠毒素的大肠杆菌是TD的主要原因,所有试验均报告利福昔明与安慰剂之间的不良事件无差异。结论。利福昔明可以预防由非侵入性肠病原体引起的TD。治疗侵入性肠病原体还需要进一步的研究。 [2012年10月3日,首次在线发布后修正:“利福昔明可以保护TD”被替换为“利福昔明可以预防TD”。]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号